Context: Incyte Corporation is a Delaware corporation headquartered in Wilmington, New Castle County, Delaware. Incyte has aggressively defended Jakafi in court. In October 2025, it secured a consent judgment and permanent injunction against Hikma Pharmaceuticals in the District of New Jersey, blocking Hikma’s generic ruxolitinib until all five core patents-in-suit expire. That litigation bought Incyte time until December 2028. Separately, Incyte’s Jakafi (ruxolitinib), a JAK1/JAK2 inhibitor, generated $2.41 billion in net product revenue in 2022. The drug treats myelofibrosis, polycythemia vera, and graft-versus-host disease. Its core composition patents were set to expire in late 2028, but the FDA granted a six-month pediatric exclusivity extension, pushing the earliest U.S. generic entry to December 2028. This cliff is one of the most critical financial threats to Incyte’s long-term revenue.
To Read The Full Story
Continue reading your article with a Membership